SCHEMBL4875661

SCHEMBL4875661

N#CC1CCC(F)(F)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20246274 0.84
SCHEMBL20246241 0.84
SCHEMBL15137978 0.84
SCHEMBL22279615 0.79
SCHEMBL1956196 0.74
SCHEMBL1956200 0.74
SCHEMBL1956198 0.74
SCHEMBL12551024 0.72 CYP11B2 (0.33)
SCHEMBL29114031 0.72
SCHEMBL697501 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122051368-A Preparation method of gel electrolyte, quasi-solid lithium ion battery containing gel electrolyte and application of quasi-solid lithium ion battery 江苏国轩新能源科技有限公司 2026-05-15 CN disclosed
US-20260049062-A1 SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LTD (CN) 2026-02-19 US disclosed
CN-121260927-A Lithium ion battery electrolyte and application thereof 远景动力技术(江苏)有限公司 2026-01-02 CN disclosed
EP-4622968-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2025-10-01 EP disclosed
CN-115803322-B SARS-COV-2 inhibitors with covalent modifications for treatment of coronavirus infection 英矽智能科技知识产权有限公司 2025-05-13 CN disclosed
CN-113382767-B Urea compounds having substituents 第一三共株式会社 2024-12-24 CN disclosed
EP-4426682-A1 SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS Insilico Medicine IP Limited (HK) 2024-09-11 EP disclosed
CN-118510759-A SARS-COV-2 inhibitors for treatment of coronavirus infection 英矽智能科技知识产权有限公司 2024-08-16 CN disclosed
WO-2024109923-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2024-05-30 WO disclosed
US-20240025860-A1 SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS INSILICO MEDICINE IP LIMITED (HK) 2024-01-25 US disclosed
WO-2013107405-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-25 WO disclosed
WO-2013107291-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-25 WO disclosed
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2013-07-18 US disclosed
CN-101233098-A Process for the preparation of geminal ((difluorocycloalkyl) methyl) amines ASTRAZENECA AB (SE) 2008-07-30 CN disclosed
US-20080167488-A1 Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines ASTRAZENECA AB (SE) 2008-07-10 US disclosed
US-20080167488-A1 Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines ASTRAZENECA AB (SE) 2008-07-10 US disclosed
US-20080167488-A1 Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines ASTRAZENECA AB (SE) 2008-07-10 US disclosed
EP-1912930-A1 PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. AstraZeneca AB (SE) 2008-04-23 EP disclosed
WO-2007013848-A1 PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. ASTRAZENECA AB (SE) 2007-02-01 WO disclosed
WO-2007013848-A1 PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. ASTRAZENECA AB (SE) 2007-02-01 WO disclosed